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Small cell lung cancer (SCLC) is characterized by prevalent circulating tumour cells (CTCs),
early metastasis and poor prognosis. We show that SCLC patients (37/38) have rare CTC
subpopulations co-expressing vascular endothelial-cadherin (VE-cadherin) and cytokeratins
consistent with vasculogenic mimicry (VM), a process whereby tumour cells form
‘endothelial-like’ vessels. Single-cell genomic analysis reveals characteristic SCLC genomic
changes in both VE-cadherin-positive and -negative CTCs. Higher levels of VM are associated
with worse overall survival in 41 limited-stage patients’ biopsies (Po0.025). VM vessels are
also observed in 9/10 CTC patient-derived explants (CDX), where molecular analysis of
fractionated VE-cadherin-positive cells uncovered copy-number alterations and mutated
TP53, conﬁrming human tumour origin. VE-cadherin is required for VM in NCI-H446 SCLC
xenografts, where VM decreases tumour latency and, despite increased cisplatin
intra-tumour delivery, decreases cisplatin efﬁcacy. The functional signiﬁcance of VM in SCLC
suggests VM regulation may provide new targets for therapeutic intervention.
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S
mall cell lung cancer (SCLC) accounts for B15% of lung
cancer cases,B200,000 deaths worldwide per annum and is
characterized by early dissemination1. Approximately 33%
of SCLC patients present with cancer conﬁned to one hemithorax,
referred to as limited-stage (LS) disease. However, the majority of
patients present with Extensive-Stage (ES) disease with
involvement of lymph nodes and with distant metastases2. Most
patients initially respond to platinum-based chemotherapy, but
usually relapse and acquire chemo-resistant disease3 such that the
median overall survival (OS) is 9–12 months and 5-year survival
is o5% (ref. 4). Advances with targeted therapies are yet to
materialise and chemotherapy regimens have remained
unchanged for almost three decades5. Improved understanding
of SCLC biology is essential to instruct development of improved
treatments, for example, by targeting SCLC stem cells6 or
overcoming mechanisms of chemotherapy resistance.
First reported in uveal melanoma7, vasculogenic mimicry
(VM) describes the ability of aggressive tumour cells to
trans-differentiate, acquiring endothelial cell behaviour that
enables de novo generation of tumour-derived vascular
networks and a micro-circulation that is independent of
non-cancer host cells8. VM is evaluated in clinical specimens by
immunohistochemical (IHC) analysis of Periodic Acid Schiff
(PAS) positive, CD31 negative vessels9. PAS stains basement
membranes including laminin, collagen and glycogen10 and
CD31 is an endothelial cell marker. A systematic review with
meta-analysis of VM, including 3,062 patients with multiple
cancer types, showed that VM was positively correlated with
worse 5-year OS11 and VM is linked to promotion of aggressive
disease and metastatic spread12. The transcriptional signature
of VM13–15 shares components with that of ‘stemness’ and
Epithelial-to-Mesenchymal Transition (EMT), key attributes
involving tumour plasticity during metastasis and resistance to
chemotherapy16. Furthermore, expression of ‘stem’ cell markers
was associated with VM in Ewing’s sarcoma17 and in a
subpopulation of breast cancer cells18. Key molecular regulators
of VM identiﬁed in other cancer types, include a VM-related anti-
coagulant role for Serpine2 and Slpi in a preclinical breast cancer
model12. Transmembrane proteins involved in adhesion and
cellular polarity are upregulated in aggressive VM-forming cells,
including Claudin-4, required for formation and maintenance of
endothelial and epithelial tight junctions in breast cancer cells19
and Vascular Endothelial (VE)-Cadherin, a transmembrane cell
adhesion molecule identiﬁed as a key regulator of VM
in aggressive melanoma20. There are no previous reports of
VM in SCLC, although it was described in Merkel cell carcinoma,
which, like SCLC, is of neuroendocrine origin21.
We argue that if VM contributes to tumour cell dissemination
in patients, then the VM phenotype is likely to be represented
within circulating tumour cells (CTCs), as tumour cells forming
vessel walls have easy access to the bloodstream. We previously
reported the high prevalence and prognostic signiﬁcance of CTCs
in SCLC22 and for the ﬁrst time we report the expression of
VM-associated VE-cadherin in a rare subset of SCLC CTCs. We
also demonstrate the presence of VM in SCLC patient tissues,
CTC patient-derived explant (CDX) models23 and a VE-cadherin
expressing SCLC xenograft. Given previous controversy
surrounding the tumour origin of VM cells24–26, we sought
genomic veriﬁcation that SCLC cells, rather than endothelial cells,
were responsible for observed VM phenotypes. Finally, we asked
whether VE-cadherin has functional signiﬁcance in SCLC with
respect to tumour growth kinetics, the intra-tumoural delivery
and efﬁcacy of cisplatin (used together with etoposide as SCLC
standard of care). We hypothesize that in vivo, VM may promote
opposing impacts on tumours; on the one hand VM may aid drug
and nutrient delivery, on the other, it may endow an aggressive,
drug resistant, ‘stem-like’ phenotype that could contribute to
dissemination, metastasis, disease relapse and shortened patient
survival in this dismal disease22.
Results
A rare subset of SCLC CTCs exhibit a VM phenotype. We
hypothesized that if SCLC cells line VM vessels, then these cells
would have ready access into the circulation. Using VE-cadherin as
a VM biomarker20, we assessed its expression in SCLC cytokeratin
(CK)-positive CTCs using ISET (isolation by size of epithelial
tumour) microﬁltration of patient blood samples that captures cells
larger than 8mm (median SCLC cell size 12.5–14.1mm (ref. 27);
Fig. 1). Thirty eight chemo-naı¨ve SCLC patients were consented to
a prospective biomarker programme for the investigation of blood-
borne biomarkers in lung cancer, conducted at the Christie NHS
Foundation Trust, Manchester, United Kingdom. Each patient had
DAPIþVE/pan-CK, CKþVE/CD45VE CTCs (Fig. 1a and
Supplementary Fig. 1a) that ranged from 0.25–403, (median 68,
mean 100) CTCs per ml. All but 1 of these patients (patient 1)
exhibited a rare subpopulation of DAPIþVE/CKþVE/
VE-cadherinþVE CTCs (Fig. 1a and Supplementary Fig. 1).
DAPIþVE/CKþVE/VE-cadherinþVE CTC number ranged from
0–154 (median 6, mean 21) CTCs per ml (Fig. 1b, upper panel)
highlighting the challenge of identifying this CTC subpopulation.
The proportion of VE-cadherin expressing CTCs ranged from
0–100% (median 12%, mean 23%) of all DAPIþVE/CKþVE
CTCs (Fig. 1b lower panel).
For 24 of the ES SCLC patients’ blood samples assessed by
ISET, we were able to access a matched needle-core biopsy in
which to evaluate VM using PAS and anti-human anti-CD31
IHC. However, the poor quality of these biopsies (especially crush
artefact28), combined with the low percentage of tumour content,
made it impossible to assess VM robustly in this type of sample
and an alternative source of SCLC tumour samples was sought to
assess VM.
VM is present and prognostic in LS SCLC. A tissue microarray
(TMA) of LS SCLC (n¼ 41) was stained with PAS and
anti-human anti-CD31 to investigate the presence of VM (Fig. 2).
The clinical characteristics of these patients are summarized in
Supplementary Table 1. Figure 2a shows PAS-positive laminin
and collagen networks (pink) surrounding tumour cells,
identiﬁed by enlarged nuclei (blue) and nuclear moulding.
PASþVE/CD31þVE endothelial vessels (pink/brown) and
PASþVE/CD31VE VM vessels (pink) were clearly deﬁned
(Fig. 2b). VM (Fig. 2b red arrow) and endothelial (Fig. 2b black
arrow) vessels were present in all patient specimens.
The VM ratio, expressed as a percentage of total vessels (VM
vessels per core/total vessels per core 100) ranged from 0 to 50%
(mean 15.5%, median 12.1%) and receiver operating characteristic
analysis for 3-year survival showed an area under the curve of 0.78
(s.e. 0.09, 95% conﬁdence interval 0.61–0.97, P¼ 0.008;
Supplementary Fig. 2a,b). Over a range of VM ratios, a ‘cutoff’
of 11% yielded greatest sensitivity and speciﬁcity (Supplementary
Fig. 2c). Univariate survival analysis demonstrated that patients
with a VM ratio 411% had a reduced 3-year survival (8.3 versus
47.1% alive at 3 years P¼ 0.015) and median OS (13.0 versus 23.8
months, log-rank P¼ 0.025) compared with those patients with a
tumour VM ratio of o11% (Fig. 2c and Supplementary Table 2).
VM is present in CDX models. Given the limited tumour
availability for this and indeed most studies of SCLC, we sought to
conﬁrm that VM occurs in SCLC, exploiting our recently described
CDX models23. CDX share classic SCLC histological features with
patient primary biopsies and cytological specimens (expression of
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neuroendocrine markers and CKs) and mirror patients’ response
to chemotherapeutics23 (Fig. 3a). In addition, CDX provide
signiﬁcantly more tumour for VM analysis compared with
standard bronchoscopic biopsies (18.9 versus 1.0mm2, unpaired
t-test, Po0.0001; Fig. 3b). Using a speciﬁc anti-murine anti-CD31
antibody with PAS staining, we identiﬁed VM networks in 9/10
CDX models derived from 8 SCLC patients (Fig. 3c). Areas of CDX
evaluated for VM were negative for Masson trichrome staining (for
example, Fig. 3c right panel) consistent with minimal murine
stromal tumour inﬁltration. VM networks in CDX ranged from
0.00–3.06VM vessels per mm2 (mean 1.05VM vessels per mm2,
median 0.83VM vessels per mm2; Fig. 3d).
Genetics of VM vessel cells in CDX show human tumour origin.
There has been considerable controversy over whether VM vessels
are comprised of tumour cells or are an aberrant co-option of
healthy somatic cells (reviewed in refs 24–26). Previous studies in
speciﬁc tumour types demonstrated the tumour origin of VM
vessels either by expression of tumour-speciﬁc structures (such as
melanosomes in uveal melanoma7) or the presence of an
introduced mCherry transgene in breast cancer cell lines grown
as tumour xenografts12. Lacking a marker that would categorically
label only SCLC cells, we sought genetic evidence that vessels
deﬁned as VM by PASþVE/CD31VE staining were indeed
composed of SCLC cells. We previously reported the generation of
CDX3 ref. 23 and here, in two replicate studies (CDX3$ and
CDX3#, schematic Fig. 4a), we identiﬁed regions of VE-cadherin
expressing cells enriched for VM identiﬁed by PAS/anti-murine
anti-CD31 antibody IHC (Fig. 4b). Laser capture micro-dissection
(LCM) was performed on ‘VM-low’ (r20% cells with
PASþ /CD31 staining) and ‘VM-high’ regions (Z75% cells
PASþVE/CD31VE staining; Fig. 4b). Additional serial sections
were stained for VE-cadherin, and for cresyl violet to identify the
region for LCM (Fig. 4b). VE-cadherin expression in whole
sections of CDX3 tumours was between 5–40% (determined by a
Deﬁniens algorithm) and co-localised with regions enriched for
VM (deﬁned by percentage of cells that were PASþVE/CD31VE;
Fig. 4b). As expected, Masson trichrome staining was evident at the
tumour periphery demonstrating murine stroma in these regions
(Supplementary Fig. 3), this murine stroma and muscle was
subsequently used as controls to conﬁrm our ability to distinguish
murine from human sequence reads in the genomic analysis of
CDX LCM regions (Fig. 4c and Supplementary Table 3). DNA
was extracted from CDX LCM regions and subjected to
next-generation sequencing (NGS) with all sequencing reads that
aligned to the mouse genome eliminated from the analysis to
identify the presence of human-speciﬁc sequences (Fig. 4c). For the
germline control sample, which does not include any mouse
sequences, the unique human reads were identiﬁed as being
70% with a similar proportion of unique human sequences also
seen for the VM-high, VM-low regions and CDX bulk tumour
samples (68–72% Fig. 4c) conﬁrming the human origin of the
dissected regions.
Having demonstrated that LCM VM-high regions had enriched
expression of VE-cadherin (Fig. 4b), a further two CDX3 tumours
(CDX3a and b) were freshly disassociated to single cells, depleted of
mouse cells with immunomagnetic beads coupled to anti-murine
anti-MHC1 antibody and stained for murine MHC1 and human
VE-cadherin. Tumour cell suspensions were sorted by ﬂow
cytometry into three subpopulations (in duplicate) of 410,000
cells, total mouse MHC1 ve cells (bulk tumour), mouse
MHC1VE/VE-cadherinVE cells and mouse MHC1VE/VE-
cadherinþVE cells (Fig. 5a,b). DNA was extracted from each
subpopulation and subjected to low-pass NGS to assess CNA.
Minimal evidence of murine read contamination was seen in
samples (range 0–2.5% of total reads; Supplementary Table 4),
clearly demonstrating samples were of human origin. Although
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Figure 1 | ISET-ﬁltered CTCs from patients with either LS or ES SCLC co-express VE-cadherin and CKs. (a) Pseudo-coloured ISET ﬁlters stained with
DAPI (white) and antibodies to pan-CK (green), CD45 (red) and VE-cadherin (blue). CTCs are classiﬁed as DAPIþVE/CD45VE/CKþVE. Scale bar,
20mm. (b) Top panel, total CTC counts per ml for CKþVE/VE-cadherinþVE CTCs (blue bars) versus CKþVE/VE-cadherinVE CTCs (green bars) are
shown for patients 1 to 38. (b) Bottom panel, the percentage of CKþVE/VE-cadherinþVE CTCs (blue bars) versus CKþVE/VE-cadherinVE CTCs (green
bars) is shown for patients 1–38.
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some differences were seen between CDX3a and CDX3b, there was
striking similarity across all CNA proﬁles and all harboured
characteristic chromosome 17p loss, a hallmark of SCLC29,30
(Fig. 5c). Targeted sequencing of the same FACS-sorted
subpopulations, including the human VE-cadherin-positive cells,
conﬁrmed the previously identiﬁed TP53 mutation
(chr17:7578190:T4C (p.Y220C); ref. 22; (Fig. 5d,e)). Taken
together the combined data (Figs 4 and 5) strongly support that in
SCLC, VE-cadherin-positive VM vessels are tumour cell derived and
not the manifestation of co-option of murine host endothelial cells.
Single-cell CNA conﬁrms VE-cadherin-positive cells are CTCs.
We sought to determine whether freshly isolated, single CTCs
co-expressing VE-cadherin and CKs had CNA proﬁles consistent
with tumour origin. Blood samples (3 10ml) were collected
from an ES SCLC patient consented to a prospective biomarker
programme for the investigation of blood-borne biomarkers in
lung cancer, conducted at the Christie NHS Foundation
Trust, Manchester, UK. The ﬁrst blood sample underwent
EpCamþVE/CKþVE CTC enumeration via CellSearch (Janssen
Diagnostics, LLC) and contained 156 CTCs per ml, the second,
parallel blood sample was analysed using marker-independent
High Deﬁnition Single Cell Analysis (HD-SCA, see the ‘Methods’
section) which identiﬁed 501 CTCs per ml. The lower number of
CTCs in the CellSearch analysis most likely reﬂects the
presence of EpCamVE CTCs identiﬁed by HD-SCA but not by
CellSearch, as we previously observed using another
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Figure 5 | FACS and genomic analysis of VE-cadherin-positive CDX tumour cells. (a) Schematic representing generation of CDX3 and subsequent
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using Hidden Markov Model (HMM), red¼ copy-number gains, blue¼ copy-number losses. (d) VAF of TP53 (p.Y220C) mutation in sorted cell
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marker-independent CTC platform31. Plasma was obtained from
the third blood sample and processed for circulating tumour
DNA (ctDNA) analysis32,33.
Cells identiﬁed by HD-SCA assay were stained using immuno-
ﬂuorescent-labelled antibodies to panCKs (green), CD45 (red),
DAPI (white) and VE-cadherin (blue; Fig. 6). Using this approach,
it was possible to identify both VE-cadherin-positive and -negative,
CK-positive CTCs (Fig. 6a). Low-pass genome-wide CNA analysis
was performed on 24 isolated single cells (Fig. 6a and
Supplementary Fig. 4) and detailed proﬁles of VE-cadherin-
positive and -negative, CK-positive CTCs were compared with a
typical white blood cell (Fig. 6a). Notably, loss of chromosome 13q
containing RB1 was observed in both VE-cadherin-positive
and -negative CK-positive CTCs. We also evaluated the CNA
proﬁle of this patient’s ctDNA which was compared with the
CNA proﬁles of the CTCs in their matched blood sample. This
comparison showed that the CTC and ctDNA CNA proﬁles are
highly related and typical of SCLC tumours29,30 (Fig. 6a,b).
Although loss of chromosome 17p (harbouring TP53, seen in
50–60% of SCLC30) was not seen in this patient, targeted
sequencing of their ctDNA identiﬁed non-synonymous TP53 and
RB1 mutations (Supplementary Table 5) in keeping with the
frequent mutation of these genes in SCLC34.
VE-cadherin plays a functional role in SCLC VM. Seminal
studies of VM in melanoma demonstrated VE-cadherin was
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Figure 6 | Single-cell CNA analysis of VE-cadherin-negative and -positive CTCs from an ES SCLC patient. (a) CTCs identiﬁed using the HD-SCA assay:
cells were stained with DAPI (white) and antibodies to CKs (green), CD45 (red) and VE-cadherin (blue) and pseudo-coloured. Top panel, DAPIþVE/
CD45VE/CKþVE/VE-cadherinþVE CTC; middle panel, DAPIþVE/CD45VE/CKþVE/VE-cadherinVE CTC; bottom panel, DAPIþVE/CD45þVE/CKVE/
VE-cadherinVE white blood cell (WBC). Arrows link to the respective CNA analysis of the indicated cell, showing loss of 3p, gain of 5p including TERT and
hemizygous loss of RB1 on 13 in CTC. Major chromosome losses (blue arrow) and gains (red arrow) highlighted above. The selected WBC in contrast has a
characteristic ﬂat CNA proﬁle indicative of healthy somatic cells. Representative images and proﬁles are shown. Scaled  10 images from the scanner are
shown for CD45, while remaining images were acquired at 40. Scale bar, 10mm. (b) CNA analysis of matched patient ctDNA: the GC-normalized and
mappability corrected read counts (log2 scale) were segmented using Hidden Markov Model (HMM), red¼ copy-number gains, blue¼ copy-number losses.
Major chromosome losses (blue arrow) and gains (red arrow) highlighted above and match pattern identiﬁed by single CTC CNA.
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essential for VM-associated network formation on matrigel. These
VM-like structures have been shown not only to be cellular
extensions, but perfusable functional vessels20. Gene-expression
proﬁling conﬁrmed that VE-cadherin was upregulated in C8161
uveal melanoma cells competent for VM network formation13–15.
These studies also demonstrated that depletion of VE-cadherin
from C8161 cells, led to abrogation of VM network formation
in vitro and VM in vivo20. Subsequent studies validated a
functional role of VE-cadherin in glioblastoma and oesophageal
cancer VM34,35. To address the role of VE-cadherin in SCLC VM,
a panel of SCLC cell lines were screened for VE-cadherin
expression and NCI-H446 (H446) was selected for functional
studies (Fig. 7a and Supplementary Fig. 5). H446 cells produced
VM-like networks on matrigel which was abolished after
VE-cadherin knockdown (VE-cadherin KD) using shRNA; no
effect was seen with the non-targeting shRNA transduced cell
line control (Fig. 6b). VM-like networks were absent in SCLC
cell lines that did not express VE-cadherin, for example,
NCI-H1048 (H1048; Fig. 6b). Altogether these data suggest a
functional role of VE-cadherin in branching network formation by
SCLC cells in vitro.
We then asked whether reduced VE-cadherin expression
reduced VM in H446 xenografts in vivo. VE-cadherin KD cells
grown as xenografts maintained a signiﬁcant reduction in
VE-cadherin expression (using the human-speciﬁc antibody)
throughout the study (91.0 versus 1.5% of tumour cells stain for
human VE-cadherin for H446 parental versus H446 VE-cadherin
KD, Po0.0001; Fig. 7c,d, Supplementary Fig. 6). The reduction of
tumour VE-cadherin expression correlated with reduction in
VM vessels (9.36 versus 2.49 VM scores for parental H446
versus H446 VE-cadherin KD P¼ 0.0005; Fig. 7e). In addition,
we demonstrated that reduction in VM vessels impacted tumour
growth dynamics; on average VE-cadherin KD H446 tumours
had a 22.3-day increase in lag time to reach a tumour volume of
200mm3 (H446, 21.0 days versus H446 VE-cadherin KD, 43.3
days, Po0.0001; Fig. 7f,g).
VE-cadherin KD impairs cisplatin delivery into tumours. We
hypothesized that the presence of VM might increase the delivery
of chemotherapy into tumours. To test this hypothesis, we assessed
the intra-tumoural delivery of cisplatin using an antibody to
cisplatin–DNA adducts for tumours with reduced VM due to
VE-cadherin KD (Fig. 7c). Cisplatin–DNA adduct formation
in vivo in VE-cadherin KD tumours versus parental controls was
decreased twofold, 1 h following a single dose of cisplatin (i.p.), in
size-matched tumours (Fig. 8, left panel); 8.4 versus 4.0% of nuclei
stained positively for cisplatin adducts in H446 parental versus
H446 VE-cadherin KD xenografts (P¼ 0.0052; Fig. 8, right panel).
We then asked whether reduction in cisplatin uptake by
VE-cadherin KD tumours reﬂected intrinsic differences in
intracellular drug inﬂux/efﬂux and subsequent response to
cisplatin. H446 parental and H446 VE-cadherin KD cells were
assessed in vitro for sensitivity to cisplatin. Knockdown of
VE-cadherin led to a signiﬁcant increase in sensitivity to cisplatin
in vitro (IC50 12.29 versus 3.23 nM, for H446 parental versus
H446 VE-cadherin KD, Po0.0001; Supplementary Fig. 7a,b),
consistent with the reduced cisplatin uptake by tumours (Fig. 8)
due to impaired drug perfusion rather than a cell intrinsic increase
in cisplatin resistance.
VE-cadherin knockdown increases chemosensitivity in vivo.
We next sought to investigate the impact of VE-cadherin
knockdown with attendant reduced VM on tumour responses
in vivo to the standard of care chemotherapy doublet, cisplatin
and etoposide. Although H446 VE-cadherin KD cells were more
sensitive to cisplatin in vitro (Supplementary Fig. 7), knockdown
of VE-cadherin did not affect sensitivity of cells to etoposide
in vitro (IC50 2.75 versus, 3.00 nM for H446 parental H446 versus
VE-cadherin KD, P¼ 0.600; Supplementary Fig. 8). Mice were
implanted with H446 parental or H446 VE-cadherin KD cells and
tumours were allowed to grow to 200mm3 before being
randomised and dosed with a single dose of 5mg per kg cisplatin
and 8mg per kg etoposide on 3 consecutive days (i.p.), or
equivalent vehicle. H446 parental tumours had a minimal
response to dosing with cisplatin/etoposide when compared with
vehicle-treated animals (Fig. 9a). In contrast, a reduction in
tumour volume (percentage of tumour volume change relative to
size at randomization) occurred with H446 VE-cadherin KD
tumours following cisplatin/etoposide treatment (mean  43.4%
reduction, median  47.9% reduction, range  9.4% to  68.1%
reduction; Fig. 9a). Treatment of H446 parental xenografts with
cisplatin/etoposide led to a 5.50-day median increase in
survival compared with vehicle-treated mice (P¼ 0.028; Fig. 9b).
Treatment of H446 VE-cadherin KD with cisplatin/etoposide
resulted in an 18.50-day median increase in survival (P¼ 0.0003)
compared with vehicle-treated mice (Fig. 9b). No signiﬁcant
difference in survival was seen between vehicle-treated
H446 parental and H446 VE-cadherin KD tumours following
randomization (P¼ 0.84; Fig. 9b).
Discussion
VM has been described in several human cancers and associated
with pluripotent ‘stem’ cell marker expression, aggressive
disease and poor patient outcomes13 with emerging evidence of
VM involvement with tumour dissemination and metastasis12.
This association with aggressive disease has led to efforts to
seek VM-targeted therapies36. We posited that if VM enhanced
haematogenous dissemination, cells with a VM phenotype would
be present in the circulation of cancer patients. Here, we report
for the ﬁrst time, that a rare subset of CTCs in SCLC express
VE-cadherin, an established marker of VM (Figs 1 and 6). We
infer that this subpopulation of VM CTCs may support VM
network capability in secondary tumours.
We show that VM vessels are present in SCLC patient tumour
specimens and that a high VM ratio correlates with poor prognosis
in LS disease (Fig. 2, Supplementary Fig. 2 and Supplementary
Table 2), observing that 21 of the 29 LS patients with survival o3
years have a high VM ratio. This result is consistent with the
hypothesis that VM acts through aggressive tumour ‘stem-like’
phenotypes, and tumour plasticity6,37, leading to worse clinical
outcomes. Furthermore, 7 out of the 10 LS patients who survived
45 years, (17% of the total cohort studied) had low VM ratios. As
the reported 5-year survival rate for LS disease is 12 15%
(refs 38–40), VM status may be a novel prognostic biomarker. A
prospective study will be essential to conﬁrm the negative impact of
VM on SCLC prognosis and tractable surrogate models are needed
to interrogate the molecular regulation of VM and investigate
further its impact on SCLC biology and response to treatment.
Obtaining tumour specimens for research is challenging in
SCLC where o5% patients undergo tumour resection38.
The development of CDX affords a new opportunity to study
SCLC biology. We conﬁrm here that ample CDX tissue, relevant
to the donor patient, can be generated for VM analysis, not
possible using bronchoscopic biopsies (Fig. 3a,b). CDX models
will also permit putative VM-targeted drug testing, for example,
of therapies that inhibit VE-cadherin signalling41,42. Mutations in
Notch family genes have been recently reported in 25% SCLC29
and whilst these signalling networks are complex, it is notable
that inhibitors of Notch signalling are reported to preferentially
target ‘stem-like’ VM tumour cells43–45.
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Figure 7 | Functional signiﬁcance of VE-cadherin expression for SCLC VM in vitro and in vivo. (a) Western blot analysis of VE-cadherin expression levels
in VM proﬁcient C8161 melanoma cells and H446, H446 non-silencing empty vector controls, H446 VE-cadherin shRNA knockdown and H1048
SCLC cells. (b) VM-like network formation on matrigel for VE-cadherinþVE cells (C8161, H446 and H446 E.V) and VE-cadherinVE cells (H1048 and
H446 VE-cadherin KD) lacking network formation. Representative images are shown for n43 experiments. Scale bar, 200mm. (c) Left panel,
representative images of anti-human anti-VE-cadherin staining in H446 parental and H446 VE-cadherin KD xenografts. Scale bar, 50 mm. (c) Right panel
percentage of cells positive for VE-cadherin in H446 and H446 VE-cadherin KD xenografts (***P¼0.0001, two-tailed t-test), n¼ 10 animals per group.
(d) Western blot analysis VE-cadherin expression in H446 and H446 VE-cadherin KD xenografts (n¼ 6 tumours for each group). (e) Left panel,
representative images of anti-mouse anti-CD31/PAS staining in H446 Parental and H446 VE-cadherin KD tumours. Scale bars, 50 mm. (e) Right panel VM
ratio in H446 parental (n¼ 10) and H446 VE-cadherin KD xenografts (n¼8; ***P¼0.0005, two-tailed Mann–Whitney’s test). (f) Tumour growth rates in
H446 (black) and H446 VE-cadherin KD (grey) tumours (n¼ 10 animals per group). (g) Days to 200mm3 volume tumours in H446 and H446
VE-cadherin xenografts KD (n¼ 20 animals per group, (***Po0.0001, two-tailed t-test). Error bars show s.e.m.
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Whether VM vessels are derived from bona ﬁde tumour cells
that have trans-differentiated, or instead represent a cell
subpopulation of endothelial lineage, has remained somewhat
controversial regarding cancer types where there is an absence of
speciﬁc tumour markers. Here, we present the ﬁrst genomic
evidence in CDX that VE-cadherin-positive VM vessels are not
composed of mouse endothelial cells, but rather they are human
SCLC cells (Figs 4 and 5 and Supplementary Tables 3 and 4).
Although there is a VE-cadherin expressing VM CTC
subpopulation in the vast majority of patents, the actual numbers
of VM CTCs detected are low (Fig. 1b). Low numbers of
VE-cadherin expressing CTCs were also seen for the patient
chosen for HD-SCA analysis with only a single VE-cadherin
expressing CTC detected from the 18 CTCs examined (Fig. 6 and
Supplementary Table 5). Nevertheless, the single VE-cadherin
expressing CTC exhibited essentially the same copy-number
gains and losses observed in the VE-cadherin CTCs and the
corresponding patient ctDNA (Fig. 6, Supplementary Fig. 4 and
Supplementary Table 5) clearly indicating the common SCLC
origin of all CTCs examined.
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We next addressed the pivotal question of whether VM is of
functional signiﬁcance in SCLC using VE-cadherin KD H446 cells
(Fig. 7). Knockdown of VE-cadherin signiﬁcantly reduced VM and
altered tumour growth kinetics. We speculate that the increased
latency for tumour growth observed with this reduction in tumour
VM may result from an enhanced requirement for host angiogen-
esis to occur to supply nutrient and oxygen for tumour growth.
Reduction of tumour VM also affected how SCLC xenografts
responded to chemotherapy, consistent with the concepts linking
‘stem cell’ like plasticity, VM and drug resistance46,47. Despite the
observed increased cisplatin delivery to SCLC xenograft tumours
with unperturbed VM (Fig. 8), there was decreased response to
cisplatin and etoposide (Fig. 9) compared with that in the
corresponding xenografts with reduced VE-cadherin expression
and reduced VM. As this xenograft model system consists of a
parental tumour where all cells express VE-cadherin and a VE-
cadherin shRNA knockdown counterpart where all detectable VE-
cadherin expression was lost (Fig. 7d), we were unable to assess
whether there would be an enrichment of chemo-resistant
VE-cadherin-positive cells following chemotherapy. It does,
however, provide an initial proof of concept that VE-cadherin-
positive cells competent for VM may be one of many mechanisms
of cisplatin resistance in SCLC. Consistent with this hypothesis in
another neuroendocrine tumour, Merkel cell carcinoma of the
skin, VM-rich areas of tumour were refractory to platinum-
etoposide chemotherapy21. Taken together, the data comparing
SCLC cells with and without VE-cadherin knockdown
demonstrate that VE-cadherin plays a functional role in SCLC
VM, as seen in melanoma and glioblastoma20,35. Overall, our data
suggest that even though rare, VM competent SCLC cells may be
able to promote outgrowth of chemo-resistant clones preceding
treatment failure. Future studies will focus on the modulation of
VE-cadherin expression in CDX models and lineage tracing of
VE-cadherin expressing cells in vivo before and after therapy.
Furthermore, a prospective study exploring VE-cadherin
expression in biopsies or (more readily available) CTCs at
baseline and again at disease progression with chemotherapy
resistance will highlight to what extent VE-cadherin-positive
tumour cells are enriched during development of
chemoresistance in the clinic. With a recent resurgence in
interest in VM26, further studies are warranted to determine
precisely how VE-cadherin signalling regulates VM in SCLC and
how VE-cadherin signalling could be exploited as a therapeutic
target in this most recalcitrant cancer.
Methods
Patient samples. Patients with histological or cytological conﬁrmation of
chemotherapy-naive SCLC attending the University Hospital of South Manchester
or Christie NHS Foundation Trust were recruited to our broader spectrum of
SCLC research (European Union CHEMORES FP6 Contract number LSHC-CT-
2007-037665) according to ethically approved protocols (NHS Northwest 9
Research Ethical Committee). VM was evaluated in a TMA from 41 LS SCLC
patients48 and in blood samples from 38 LS or ES patients for enrichment of CTCs
by ISET ﬁltration (method described in ref. 49; bronchoscopic biopsies were also
obtained from 24 of the ES patients for whom CTCs were analysed. A separate
cohort of 9 ES patients provided blood samples that led to the derivation of 11
CDX23 that were used to assess the prevalence of VM vessels and for CDX3L, CNA
proﬁles of CDX tumour regions with high and low VM. Finally, CTCs from an
additional ES SCLC patient were analysed using the EPIC platform and subsequent
isolation of single CTCs for CNA proﬁling.
Immunoﬂuorescent analysis of ISET-ﬁltered CTCs. Tumour cells in 7.5ml blood
samples were immobilized on ISET ﬁlters (Metagenex) according to the manu-
facturer’s recommendations22. Cells on ISET ﬁlters were permeabilised with
phosphate-buffered saline (PBS) with 0.2% Triton X-100 (PBST), blocked with 10%
goat serum (Dako, X090710) in PBST before staining for rabbit anti-human CD45
(1:1,000, Abcam, AB10559) and mouse anti- human VE-cadherin (1:200,
eBioscience, 14-1449-82). Cells were washed twice with PBST then counterstained
with goat anti-rabbit DY550 (1:500 Thermo Fisher Scientiﬁc, Wilmington, USA,
catalogue number 84541) and goat anti-mouse Alexa-Fluor 647 (1:500 Invitrogen,
catalogue number A-21235) washed twice again in PBST then stained with anti-
human pan-cytokeratin-FITC (1:100 Sigma, clone C-11) Filters were washed twice in
PBST, incubated with DAPI (0.5mg per ml, Invitrogen D3571, 80ml, 5min), washed
twice in PBST then double-distilled water before mounting on a glass slide with
ProLong Gold anti-fade (Invitrogen P36934). Slides were left overnight at room
temperature (RT) to dry before imaging with a MIRAX automated slide scanner
(3DHistech, Budapest, Hungary). Images were reviewed with 3DHistech panoramic
viewing software (version 1.15.1.10). CTCs were deﬁned as CKþVE/CD45VE.
VM score was calculated from a 4ml blood sample as VE-cadherinþVE/CKþVE/
CD45VE CTCs/total number of CTCs per ml blood as percentage.
VM detection and scoring of TMA and CDX samples. Formalin-ﬁxed,
parafﬁn-embedded sections (4 mm) of TMA and CDX were stained by
immunohistochemistry (IHC) for pan-CK; pan-CK antibody to CKs 1–8,10, 13–16
and 19, mouse AE1/AE3, M3515, 1:60, Dako), CD56 (mouse, 1B6, NCL-CD56-
aB6, 1:100, Novocastra), synaptophysin (mouse, 27G12, NCL-L-SYNAP-299,
1:200, Novocastra), anti-human VE-cadherin (mouse, Clone16B1, 1:50,
eBioscience) anti-human CD31 (mouse,Clone JC70A, 1:100, Dako/M0823) and
anti-mouse CD31 (rabbit, a kind gift from N.R. Smith, AstraZeneca, 1:600). For all
antibodies,except Chromograin A anti-Mouse CD31, IHC assays were carried out
on a LEICA Bond Max platform, using standard protocol F50. Negative IgG
controls were performed for each tissue section and treated identically to
experimental slides.
Chromogranin A (mouse, LK2H10þ PHE5, MP-010-CM1, 1:600, Menapath)
Antibody incubations and detection were carried out at RT on a Menarini
IntelliPATH FLX (A. Menarini Diagnostics) using Menarini’s reagent buffer and
detection kits.
Antigen retrieval was performed in a pressure cooker using access super
retrieval ﬂuid (MP-606-PG1), which was incubated for 10min with protease
(MP-960-K15) on IntelliPATH. For the CD31/PAS double-staining, sections
underwent antigen retrieval in DakoCytomation Target Retrieval Solution Citrate
pH6 (S2369) at 110 C for 5min before being stained by IHC for CD31 on a
Biogenex i6000 Autostainer. Stained sections were viewed with a light microscope
at a magniﬁcation of  40 and analysed by two independent scorers (R.M.
and F.T.) without knowledge of demographic or outcome data. Suitable digital
images were captured using MIRAX brightﬁeld digital slide scanner (3DHistech)
with Panoramic Viewer software. CD31þVE Vessels/lined spaces were deﬁned as
endothelium-dependent vessels. VM channels were deﬁned as PASþVE/CD31VE
channels enclosed by SCLC cells (the absence of endothelial cells conﬁrmed by
hematoxylin-eosin staining). The entire scorable area of each section was used to
calculate the total number of VM channels and endothelium-dependent vessels.
The percentage of VM structures in relation to the total number of vessels in each
of the TMA cores or CDX sections was calculated as the ratio of VM vessels
(PASþVE/CD31VE)/total vessels (PASþVE/CD31þVE plus PASþVE/
CD31VE) per section expressed as a percentage10.
VE-cadherin expression was scored using Deﬁniens Developer XD (version
2.0.4) and Tissue Studio Portal (version 4.2 ), (Deﬁniens AG, Munich, Germany).
Regions of interest were identiﬁed through machine learning across several sections
using Deﬁniens Tissue Studio51. Nuclei were detected within these regions of
interest and classiﬁed as positive or negative for staining based on a threshold set as
a constant across all tissue sections.
IHC for cisplatin–DNA adducts in xenografts containing H446 or H446
VE-cadherin KD cells treated with cisplatin or vehicle was performed essentially as
described elsewhere51, except with the following modiﬁcations: brieﬂy, samples were
ﬁxed in methanol (10min, 4 C) and rehydrated in PBS (10min; 25 C). Cellular
RNA was digested by RNase treatment (RNase A, 200mgper ml in PBS; 100ml per
slide; Roche; 1 h; 37 C) in a humidiﬁed chamber. Cellular proteins were digested with
pre-warmed ﬁcin (Invitrogen REF 003007, ready to use) for 10min at 37 C followed
by pre-warmed proteinase K (Novocastra RE7160CE; dilute 1 drop per ml PBS) for
10min at 37 C. After blocking with Avidin/biotin block (Vector lab, SP2001) for
30min at 37 C and PBS wash, slides were incubated with primary antibody (1:1,000
in PBS with 1% casein, Millipore rat Ab against cisplatin–DNA, clone ICR4,
Cat. # MABE416) for 2 h at 37 C. Following PBS wash slides were incubated with
FITC-labelled secondary antibody (1:400, anti-rat, diluted in Ab diluent, 712-066-153,
Jackson ImmunoResearch) for 1 h at 37 C and further incubated with Alexa-Fluor
488-labelled anti-FITC antibody (1:1,000, diluted in Ab diluent, Invitrogen, catalogue
number S11223) for 30min at 37 C and counterstained with ProLong Gold Antifade
Mountant with DAPI (catalogue number P36935, Thermo Fisher Scientiﬁc).
Visualization and quantitation of antibody- and DNA-derived ﬂuorescence was
performed via low-light microscopy. Slides were blinded and the percentage of
Cisplatin–DNA-positive cells was calculated frommanual scoring of 10 random ﬁelds
at  40 magniﬁcation by two independent operators.
Statistical analysis. Statistical analysis was performed using SPSS version 20
(SPSS, Chicago, IL, USA). Fisher’s exact t-test was used to evaluate for association
between the TMA VM score and prognostic factors (hemoglobino9 g per l, white
blood cell 410 109 per l, platelets o150 109 per l, Na o135mmol per l and
LDH 4550 IU per l11). Univariate survival analysis was performed using Kaplan–
Meier analysis and differences between survival distributions were evaluated by
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Log-rank test. A P value of o0.05 was considered statistically signiﬁcant. Survival
times were calculated as time elapsed between biopsy date and date of death or last
follow-up. Patients alive at last follow-up were censored.
To determine a threshold for the TMA VM score with greatest sensitivity and
speciﬁcity for prediction of 3-year survival, receiver operating characteristic curves
were analysed to calculate area under the curves and to determine the sensitivity
and speciﬁcity of the prediction at multiple thresholds.
For in vivo studies, to detect a fourfold effect size with 80% power and a
signiﬁcance level of 0.05, a group size of n¼ 9 was required. All studies used a
minimum of 10 animals per group.
Identiﬁcation of CDX tumour regions with high and low VM. CDX3 was
derived from a male patient with ES SCLC23. CDX3 was passaged three times and
at a tumour volume of 664mm3, the tumour disaggregated with removal of dead
and murine cell contaminants (using magnetic beads) and 10,000 SCLC cells were
re-implanted into 2 female NSG mice. Mice bearing the resultant CDX3# and
CDX3$ tumours (B300–400mm3) were killed and tumours were formalin-ﬁxed.
Three consecutive sections were stained by IHC for VM (CD31/PAS),
synaptophysin and VE-cadherin (as above), to identify regions of high and low
prevalence of VM for LCM of the parallel sections and copy-number alteration
(CNA) analysis. With VM-high and -low regions thus identiﬁed, a further eight
consecutive tissue sections were cut and directly mounted on Frame slides PET
membrane (Leica Microsystems GmbH, Wetzlar, Germany) for LCM.
LCM of CDX VM-high and -low regions. Slides containing VM-high and -low
regions in were stained with 4% Alcoholic Cresyl violet and 0.5% alcoholic Eosin
(to maintain DNA quality). Separate regions of CDX3# and CDX3$ were identiﬁed
according to their VM-high (Z75% area consisting of VM contributing cells) and
VM-low phenotype (r20% area consisting of VM contributing cells) by PAS/
CD31 staining. To obtain sufﬁcient cells to asses CNA in both VM-high and -low
regions, B150 cells in each of the eight sections (that also stained for synpato-
physin by IHC in a consecutive section) were laser captured, micro-dissected from
the Frame slides (LCM 6000 B Leica Microsystem).
FACS of CDX tumours based on VE-cadherin expression. CDX3 tumours were
dissociated to single cells with Miltenyi Biotecs tumour dissociation kit according
to manufacturer’s recommendations on a gentleMACS dissociator52. Single cells
underwent immunomagnetic depletion of mouse cells and dead cells with a Dead
cell removal microbead set (Mitenyi Biotec), anti-mouse anti-MHC1 antibody
(eBioscience clone, 34-1-2s) and anti-mouse anti-IgG2aþ b microbeads over a LS
column in a MidiMACS Seperator (Miltenyi Biotec). Depleted cells were stained
with anti-human anti-VE-cadherin-biotin (mouse, 1:200 eBioscience, clone 16B1),
streptavidin-PE (1:500, catalogue number 12-4317-87, eBioscience) and anti-mouse
anti-MHC1-APC (mouse, 1:200, clone 34-1-2s, eBioscience), before undergoing
sorting by FACS to populations of 410,000 cells per group (in duplicate) on a
FACSAria III cytometer (BD Biosciences, Heidelberg, Germany). Antibody
combinations with BD CompBeads anti-mouse anti-IgG (catalogue number
552843, BD Biosciences) according to manufacturer’s recommendations were
performed for ﬂuorescence emission spectral compensation and cytometry gating
strategies were set according to ﬂuorescence minus one- stained CDX3 cells.
CNA analysis of CDX-dissected regions. DNA was extracted and ampliﬁed from
a total ofB1,200 LCM cells (150 cells in 8 sections combined) from each VM-high
and VM-low region of CDX3# and CDX3$ with PicoPLEX for whole-genome
ampliﬁcation (WGA; WGA Kit Rubicon Genomics). WGA products were puriﬁed
(Agencourt AMPure XP, Beckman Coulter) and DNA concentrations calculated
(Nanodrop1000, Thermo Fisher Scientiﬁc) and Qubit (Life Technologies). WGA
samples were assessed for quality control (Ampli1 QC kit, Silicon Biosystems,
Bologna, Italy). In parallel, DNA from passage 1, bulk CDX3 tumour (containing a
mixture of VM-high and VM-low regions) and matched patient blood to obtain
germline was extracted (DNA Mini Kit, Qiagen, Valencia, CA, USA) and used as a
positive internal control for downstream analysis. Samples passed QC if the correct-
length amplicons were visualized on a 2% agarose gel. For CNA analysis, the DNA
library was prepared from 50ng of ampliﬁed DNA (NEBNext Ultra DNA Library
Prep Kit, Illumina, New England Biolabs, Ipswich, UK). Each library was quantiﬁed
(KAPA qPCR Bioanalyzer, KAPA Biosystems, MA, USA) and equimolar amounts
were pooled and sequenced on a MiSeq Illumina platform (150 b.p. pair end).
Circulating cell-free DNA preparation and quantiﬁcation. Blood samples
collected in EDTA (ethylenediaminetetraacetic acid) Vacutainer tubes
(BD Biosciences) were used for extraction of germline DNA and blood samples
collected using Cell-Free DNA BCT tubes (Streck, Omaha, NE) were used for
extraction of circulating cfDNA from a patient with ES SCLC. Plasma from
Cell-Free DNA BCT blood samples, was separated from whole blood by two
sequential centrifugations (each 2,000g, 10min) followed by upper phase plasma
removal and stored at  80 C in 2ml aliquots32. cfDNA was isolated from 4ml of
double-spun plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen,
Hilden, Germany) as per manufacturer’s instructions. Following isolation, cfDNA
yield was quantiﬁed using the TaqMan RNase P Detection Kit (Life Technologies)
as per manufacturer’s instructions32. Germline DNA was isolated from thawed
EDTA whole blood using QIAmp Blood Mini Kit (Qiagen) as per manufacturer’s
instructions.
NGS sequencing of FACS-sorted CDX cells and patient ctDNA. Libraries for
whole-genome sequencing of cfDNA and corresponding germline DNA from the
patient with ES SCLC and FACS-sorted CDX3 tumour samples were carried out
using the Accel-NGS 2S Plus DNA Library Kit and indexing of the libraries using
NEBNext Multiplex oligos for Illumina (New England Biolabs) using a 25 ng DNA
input. Libraries were quantiﬁed by qPCR using the Library Quantiﬁcation Kit for
Illumina sequencing platforms (KAPA Biosystems, Boston, USA) as per manu-
facturer’s instructions on the LightCycler 96 System (Roche). Libraries were pooled
in equimolar proportions and paired-end sequencing (300 cycles) was performed
on the Illumina MiSeq (Illumina) benchtop sequencer using the MiSeq Reagent Kit
v2 (Illumina).
Targeted NGS analysis. Targeted NGS of 110 SCLC-associated genes for cfDNA
and corresponding germline DNA from the patient with ES SCLC was carried out
using Agilent SureSelectXT essentially as described previously33. In brief, we
enriched the 110 SCLC-associated genes using SureSelectXT Custom DNA Kit
(Agilent, Santa Clara, CA, USA) following the manufacturer’s recommendations.
The enriched DNA libraries were re-ampliﬁed using the KAPA HiFi PCR Kits and
Illumina sequencing primers for 30 cycles. Paired-end sequencing was performed
for these enriched libraries on the Illumina NextSeq 500 (Illumina) benchtop
sequencer with the NextSeq 500/550 v2 kits.
Targeted NGS of the 10 SCLC-associated genes (KRAS, TP53, RB1, PIK3CA,
PTEN, BRAF, NRAS, ALK, NOTCH1, EGFR) for the CDX3 tumour DNA samples
was carried out using custom xGen Lockdown Probes (Integrated DNA
technologies). In brief, 500 ng adaptor-ligated DNA libraries from 6 FACS-sorted
CDX3 tumour samples were pooled together and combined with 5 mg of Cot-I
DNA (Invitrogen) and 1 nmol each of blocking oligonucleotides (TS-p5 and
TS-p7). The mixture was lyophilized and then re-suspended in 1.8 ml water, 8.5 ml
2 xGen hybridization buffer and 2.7 ml xGen hybridization buffer enhancer. The
mixture was heated to 95 C for 10min. Subsequently, 3 pmol of cuxtom xGen
lockdown probes were added and allowed to hybridize for 4 h at 65 C. After
hybridization, M-270 streptavidin beads (Life Technologies) were added and
washes were performed according to the manufacturer’s recommendations. The
enriched DNA libraries were re-ampliﬁed using the KAPA HiFi PCR Kits and
Illumina sequencing primers for 30 cycles. The ampliﬁed enriched libraries were
then sequenced on the Illumina MiSeq (Illumina) benchtop sequencer using MiSeq
Reagent Kit v2 (Illumina).
Copy-number and mutation analysis of the CDX samples. Alignment and
processing of sequencing reads. Sequencing reads were aligned to the human
reference genome GRCh37/hg19 using the Burrow–Wheeler aligner (version 0.7.7)
(ref. 53) with default parameters. To remove potential contaminating mouse DNA,
we aligned the sequencing reads to mouse reference GRCm38/mm10
independently and discarded reads that cross-aligned to both human and mouse
genomes.
Copy-number analysis. The Bioconductor package HMMcopy (version 1.8.0)
(refs 54,55) was used to determine copy-number variations. Brieﬂy, the genome
was divided into 150-kb windows. Reads in each window were normalized by GC-
content and mappability. Then a Hidden Markov Model-based approach was used
to segment the data into regions of similar copy-number proﬁle and to predict a
CNA event (that is, 0, 1, 2, 3, 4 or Z5 copies of chromosome) for each segment.
Somatic mutation calling of CDX samples (IDT 10 gene enrichment). After
removing mouse reads, Picard (version 1.96, http://picard.sourceforge.net) was
used to mark duplicated reads. The alignments were sorted and indexed using
SAMtools (version 0.1.19) (ref. 56). Local re-alignment around known INDELs and
base quality recalibration were performed using Genome Analysis Toolkit (GATK,
version 3.1.1) (ref. 57). The recalibrated alignments of the tumour and matched
germline control samples were analysed in MuTect (version 1.1.5) (ref. 58) to
detect somatic single-nucleotide variants (SNVs). MuTect was run in the High-
Conﬁdence mode with default settings except that a maximum of 5 variant alleles
was allowed in the germline control (--max_alt_alleles_in_normal_count¼ 5).
ANNOVAR (version 2015 Mar 22) (ref. 59) was used to annotate the call sets.
Somatic mutation calling of cfDNA and Germline samples (Agilent 110 gene
enrichment). The aligned reads in SAM format were converted to BAM format and
sorted using Picard tools (version 1.96, http://picard.sourceforge.net). Local
re-alignment around known INDELs and base quality recalibration were
performed using GATK (version 3.1.1) on the sorted and marked duplicates BAM
ﬁles. MuTect (version 1.1.5) was used to detect somatic SNVs in the matched
tumour-germline control samples. An SNV was included in the ﬁnal call set
(Supplementary Table 5) if it fulﬁlls the following criteria: (1) variant allele
frequency (VAF) in tumour sampleZ0.025, (2) VAF in tumour is at least 5 times
higher than VAF in the germline control and (3) it is covered by least 200 reads in
both tumour and germline samples. Finally, the SNVs were annotated using
ANNOVAR (version 2015 Mar 22).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13322
12 NATURE COMMUNICATIONS | 7:13322 | DOI: 10.1038/ncomms13322 | www.nature.com/naturecommunications
HD-SCA isolation of single VE-cadherin-positive CTCs. Peripheral blood
samples were collected, stained and imaged using the HD-SCA assay1. On arrival of
blood samples, white blood cell counts were measured using a M-Series
Hematology Analyzer (Medonic, Stockholm, Sweden) to determine the blood
volume required to plate 3 million cells in a monolayer onto adhesion slides
(Marienfeld, Lauda, Germany). The erythrocyte population was lysed while rocking
the sample for 5min at RT in NH4Cl solution. The lysed blood was centrifuged at
800g and the nucleated cells were re-suspended in PBS and incubated for 40min at
37 C on the adhesion slides. To block unbound sites, slides were incubated with
7% BSA for 5min at RT. The BSA was discarded and a coverslip was attached to
dried slides before freezing at  80 C for long-term storage.
Before staining, slides were thawed and cells were ﬁxed with 2% PFA for 20min
at RT, washed with PBS and permeabilized with 100% ice-cold methanol for 5min
at RT. After washing with PBS twice, slides were blocked with 10% goat serum at
37 C for 20min. A cocktail of antibodies containing 140mg per ml pan-CK (Sigma,
St Louis, MO, USA), 0.2 mg per ml CK 19 (DAKO, Carpinteria, CA, USA),
10mg per ml CK 7 (Millipore Billerica, MA, USA), 1.6 mg per ml Alexa-Fluor
647-conjugated CD45 (Serotec, Raleigh, NC, USA) and 92 mg per ml VE-cadherin
(Cell Signalling Technology, Danvers, MA, USA) in 10% goat serum was allowed to
bind at 37 C for 40min. Residual non-binding antibody was removed by washing
with PBS twice, and a mix of 100 ng per ml DAPI, 4 mg per ml Alexa-Fluor 555 goat
anti-mouse (Thermo Fisher Scientiﬁc, Waltham, MA, USA) and 8 mg per ml
Alexa-Fluor 488 goat anti-rabbit (Thermo Fisher Scientiﬁc) were incubated at
37 C for 20min. After another round of washing, slides were dipped in dH2O and
mounting media was added before cover slips were attached using nail polish.
Slides were imaged by a custom made ﬂuorescent scanning microscope. Candidate
cells were computationally identiﬁed and presented to pathology trained personnel.
VE-cadherin-positive or -negative SCLC cells were classiﬁed and re-located for
single-cell genomics studies60.
High-content single-cell selection and CNA of CTCs. Cells were subsequently
isolated using a micropipette and subjected to WGA (WGA4, Sigma-Aldrich,
St Louis) and low-depth Illumina sequencing yieldingB1 106 uniquely mapping
reads. Copy-number proﬁles were generated by grouping the reads into 4,973
bioinformatically derived bins (B0.5Mbp) containing equal amounts of uniquely
mapping sequence reads. CNA plots were generated by plotting the ratio of unique
sequence reads per bin, and applying a smoothing algorithm to generate integer-
level copy-number values for each bin61–63. Cell clonality was assessed by
comparing the location of break points of ampliﬁcations and deletions across the
single-cell proﬁles.
Culture and siRNA knockdown of VE-cadherin in NCI-H446 cells. NCI-1048
and NCI-446 SCLC cell lines (American Type Culture Collection) were
authenticated (ampﬂstr, Applied Biosystems) and cultured in RPMI media
(Life Technologies) containing 10% fetal bovine serum (Biowest) at 37 C and
5% CO2. C8161 melanoma cells (a gift from Mary Hendrix) were cultured as above.
Cell lines were authenticated using Promega Powerplex 21 System and routinely
screened for mycoplasma within CRUK Manchester Institute’s core facility.
Viral particles containing ﬁve shRNAs (Thermo Scientiﬁc, TRCN0000054088,
TRCN0000054089, TRCN0000054090, TRCN0000054091 and TRCN0000054092)
targeted against VE-cadherin cloned separately into the pLKO.1 lentiviral vector
(Dharmacon, GE Lifesciences) and the pLKO.1 TRC Control vector (Addgene
#10879) were generated by co-transfecting Lenti-X 293T (Clontech) cells with
respective shRNA or control plasmids and pCMV-R8.91 and pMD2.G (a kind gift
from Dr Orimo, Juntendo University, Tokyo, Japan) according to manufacturer’s
recommendations48. NCI-H446 cells were transfected with virus plus 6 mg per ml
polybrene (Sigma) and selected with 1 mg per ml puromycin (Sigma) for B7 days.
Polyclonal mixes for each shRNA plus control were generated and screened for
knockdown of VE-cadherin by western blot.
Network formation on matrigel. Six well tissue culture dishes were coated with
200ml of Matrigel (BD Biosciences) and incubated at 37 C for 30min. NCI-H446,
NCI-H446 shRNA VE-cadherin, NCI-H446 PLKO.1 non-targeting shRNA, H1048
and C8161 cells were seeded onto the plates at 2.5 105 cells per well and VM
networks were imaged by phase-contrast microscopy over 72 h within 4 randomly
selected ﬁelds of view per well7.
Cisplatin delivery and efﬁcacy in vivo. NCI-H446 and H446 VE-cadherin KD
cell xenografts were grown by s.c. injection of 1 106 cells (0.1ml of serum-free
medium/matrigel 1:1) into the back mid-dorsal region of 6–8-week-old female
NSG mice. Mice were housed in individually vented caging systems, maintained at
a uniform temperature and humidity, set on a 12 h light/12 h dark environment.
Individual mouse weights and tumour volumes (calculated as (length
(tumour width)2)/2) were measured three times a week, until a tumour volume of
B250mm3, when they were assigned to experiments. To assess cisplatin delivery
animals were randomised into treatment groups (via a deterministic method
without blinding) and received either a single dose of 7.5mg per kg cisplatin i.p. or
10ml per kg vehicle i.p., they were culled 1 h later via a Schedule I method.
Tumours were half formalin-ﬁxed and parafﬁn-embedded for analysis by IHC.
To assess the impact of VM on cisplatin/etoposide efﬁcacy, animals bearing
NCI-H446 or H446 VE-cadherin KD cell xenografts received either a single dose
5mg per kg cisplatin i.p. on day 1 and 8mg per kg etoposide i.p. on days 1, 2 and 3
or 5ml per kg vehicle (0.9% salineþ citric acidþNMP) on days 1, 2 and 3 i.p.
Animals were culled via a Schedule I method when tumours reached 1,000mm3.
Tumours were formalin-ﬁxed and parafﬁn-embedded for analysis by IHC. All
procedures were carried out in accordance with Home Ofﬁce Regulations (UK) and
the UK Coordinating Committee on Cancer Research guidelines and by approved
protocols (Home Ofﬁce Project license no. 40-3306 and Cancer Research UK
Manchester Institute Animal Welfare and Ethical Review Advisory Board) and in
accordance with ARRIVE guidelines64.
Data availability. All relevant sequencing data is uploaded to the European
Genome-phenome Archive (EGA; https://www.ebi.ac.uk/ega/home) under the
accession number EGAS00001001944.
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